Valerio Therapeutics (FRA:C4X) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C4X Valerio Therapeutics FRA:C4X
37 GF Score
Price €0.82
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics FFO per Share?

FFO per Share only applies to REITs.

FRA:C4X
37GF Score
Valerio Therapeutics FRA:C4X
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valerio Therapeutics (FRA:C4X) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.82 is trading 1072.9% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:C4X:

  • FFO per Share:
  • GF Value™: €0.07 vs. price of €0.82 (1072.9% above fair value)
  • GF Score™: 37/100 with 9 warning signs

No single metric tells the full story. See the FRA:C4X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKALVIO:France
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
37GF Score

Get the complete analysis for FRA:C4X

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.82
Price
€0.07
GF Value